We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+38.9%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.13B
AUM Growth
+$1.33B
Cap. Flow
+$252M
Cap. Flow %
3.09%
Top 10 Hldgs %
38.33%
Holding
153
New
32
Increased
35
Reduced
44
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan Inc
AGN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$111M
3
ESRX
Express Scripts Holding Company
ESRX
+$60.7M
4
ABBV icon
AbbVie
ABBV
+$52.2M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$48.2M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$78.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$61.6M
3
CELG
Celgene Corp
CELG
+$61.1M
4
INCY icon
Incyte
INCY
+$58.6M
5
UNH icon
UnitedHealth
UNH
+$51.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.16%
2 Technology 0.09%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
51
DELISTED
Array Biopharma Inc
ARRY
$29.6M 0.36%
6,297,000
+972,000
+18% +$4.89M
XNPT
52
DELISTED
XENOPORT, INC.
XNPT
$28.7M 0.35%
5,546,100
+955,300
+21% +$5.76M
NXTM
53
DELISTED
NxStage Medical Inc.
NXTM
$26.9M 0.33%
2,113,000
-566,216
-21% -$7.39M
EXAS
54
DELISTED
Exact Sciences
EXAS
$26.8M 0.33%
1,893,000
-3,096,300
-62% -$41.8M
TSRO
55
DELISTED
TESARO, Inc.
TSRO
$25M 0.31%
+847,800
New +$26.7M
AGN
56
CALL
DELISTED
Allergan Inc
AGN
$24.8M 0.31%
+200,000
New +$24.4M
PTLA
57
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$24.8M 0.31%
957,700
– –
MRTX
58
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$24.3M 0.3%
1,274,332
– –
DRTX
59
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$24M 0.3%
1,785,714
– –
IBB icon
60
PUT
iShares Biotechnology ETF
IBB
$9.55B
$23.6M 0.29%
+300,000
New +$25M
PTCT icon
61
PTC Therapeutics
PTCT
$6.25B
$21.7M 0.27%
+830,100
New +$22.3M
LITS
62
Lite Strategy Inc
LITS
$33M
$21.4M 0.26%
96,225
-3,250
-3% -$586K
FPRX
63
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$21.1M 0.26%
+1,075,400
New +$18.3M
CERS icon
64
Cerus
CERS
$585M
$20.3M 0.25%
4,238,000
+863,000
+26% +$5.55M
MDT icon
65
Medtronic
MDT
$111B
$19.9M 0.24%
323,000
– –
CAH icon
66
Cardinal Health
CAH
$54.5B
$18.7M 0.23%
267,000
+36,700
+16% +$2.55M
BHC icon
67
Bausch Health
BHC
$1.69B
$17.5M 0.22%
133,000
-24,000
-15% -$3.28M
AGEN
68
Agenus
AGEN
$275M
$16M 0.2%
+257,298
New +$17.9M
JAZZ icon
69
Jazz Pharmaceuticals
JAZZ
$16.1B
$15.9M 0.2%
115,000
– –
MGNX icon
70
MacroGenics
MGNX
$245M
$13.7M 0.17%
491,897
– –
AMBI
71
DELISTED
Ambit Biosciences Corp
AMBI
$13.6M 0.17%
1,490,769
– –
IRWD icon
72
Ironwood Pharmaceuticals
IRWD
$626M
$13.3M 0.16%
+1,292,027
New +$14.5M
INO icon
73
Inovio Pharmaceuticals
INO
$84.7M
$13.3M 0.16%
+83,063
New +$11.9M
AZN icon
74
CALL
AstraZeneca
AZN
$267B
$13M 0.16%
+200,000
New +$12.9M
ABBV icon
75
CALL
AbbVie
ABBV
$465B
$12.8M 0.16%
250,000
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2014 Portfolio in Review

As of Q1 2014, OrbiMed held 153 positions worth $8.13B, up 20% from $6.8B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $252M of net new capital in Q1 2014, opening 32 new positions and adding to 35 existing holdings. Its largest new stake was Eli Lilly: 543,000 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $78.6M trimmed.

  • OrbiMed's largest Q1 2014 buy was Eli Lilly: 543,000 shares worth $32M.
  • OrbiMed added most to Allergan Inc in Q1 2014, an estimated $182M increase.
  • OrbiMed's biggest Q1 2014 reduction was Aetna Inc, cutting an estimated $78.6M.
  • OrbiMed fully exited QIAGEN NV in Q1 2014, selling an estimated $45.9M.
  • OrbiMed's ten largest holdings make up 38% of its $8.13B portfolio in Q1 2014.
  • OrbiMed opened 32 new positions and closed 13 in Q1 2014.
  • OrbiMed's portfolio value rose 20% quarter-over-quarter to $8.13B.

Based on OrbiMed's 13F filing for Q1 2014, filed 15 May 2014.